Life Competence - the first global picture on the EU-funded health research

It is now possible to have a global picture of which research organisations and which research areas were funded by the European Commission during the 2001-2006 years (6th European Research Framework Programme). The data has been generated from an online webbased database of competences, supported through an EU specific support action.

The project has been implemented by AVEDAS AG, Germany, Karolinska Institutet, Sweden and EuropaBio, Belgium. It contains all the health related projects funded by the EU during the last Research Framework Programme, as well as the principal organisations participating in these projects. The aim of this database is to increase transparency and accessibility of research competences in Europe, both for Europeans (in a recent Eurobarometer, 70% of them expressed their interest in health research) but also for other nationalities interested in participating in the European Health Research effort.

In the European Research Programme going from 2001 to 2006 (FP6), the part of the programme focussing on health research was major with its budget of € 2.4 billion supporting 680 projects. It was shared between different research areas with about 50% of the projects and budget dedicated to disease oriented research areas. Cancer is the area receiving most support with 123 projects, about 18 % of projects partly or entirely focussed on cancer, with 22 % of the budget (€ 539 million). Other important research areas are AIDS/HIV, Stem Cell Research, Diabetes, Diagnostics, Vaccines and Drug design.

An important policy in the EU is to support competitiveness by encouraging cooperation of academia and clinicians with industry, and especially with small and medium-sized enterprises (SMEs). Out of 2.438 unique partners in health research projects, 853 are from the private sector, of which 365 SMEs (15%). It means that around 20 % of the total number of SMEs in the Health sector are participating in the EU programme. The majority of partners in the programme are academic.

Another important policy in European research is international cooperation. Participation from countries outside Europe and its associated states represents about 5% of partners of health projects. The highest number of participations are from China, Russia, US and South Africa. Within Europe, about 6% of the partners are from the 12 new EU-member states and 7% of the partners are from the states associated to the EU with science and technology cooperation agreements that involved contributing to the framework programme budget.

It is expected that the 'LifeCompetence' database will have many positive implications for the Health research society in Europe and for worldwide cooperations, e.g. increased knowledge transfer, better partnerships and more efficient management of research programmes and research organisations, as well as providing a transparent information on the resources invested in funding health research at the European level.

For further information, please visit:
http://www.lifecompetence.eu

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...